Sutilain

Identification

Name
Sutilain
Accession Number
DB09379
Description

Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000 casein units of proteolytic activity.2 Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.3

Type
Biotech
Groups
Approved, Withdrawn
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Sutilaina
  • Sutilaines
  • Sutilains
External IDs
  • BAX 1515
  • BAX-1515

Pharmacology

Indication

Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.2

Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Reports indicated that sutilain exhibited a rapid and effective debridement when used for the treatment of burns, decubiti and traumatic wounds. In the case of peripheral vascular ulcerations, it did not respond in a predictable manner.1 When used, sutilain caused a rapid dissolution of the surface of the treated skin zone. However, a graftable wound bed as achieved no more rapidly than if saline soaks had been used since the enzyme appears to be ineffective in removing deep dermal elements and necrotic fat.4

Mechanism of action

Sutilain is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase.[T170]

Absorption

Sutilain is not absorbed.

Volume of distribution

This pharmacokinetic parameter is not relevant.

Protein binding

This pharmacokinetic parameter is not relevant.

Metabolism

This pharmacokinetic parameter is not relevant.

Route of elimination

This pharmacokinetic parameter is not relevant.

Half-life

This pharmacokinetic parameter is not relevant.

Clearance

This pharmacokinetic parameter is not relevant.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The toxicity has not been determined.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Travase Ointment 82000 Casein Units/gmOintmentTopicalBoots Pharmaceuticals Ltd.1987-12-311996-09-09Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
2PU6O23V1G
CAS number
12211-28-8

References

General References
  1. Coopwood TB: Evaluation of a topical enzymatic debridement agent--sutilains ointment: a preliminary report. South Med J. 1976 Jul;69(7):834-6. [PubMed:821152]
  2. Kokate C., Purohit A. and Gokhale S. (2008). Pharmacognosy (42nd ed.). Pragati Book House. [ISBN:978-81-96396-15-2]
  3. FDA approval [Link]
  4. US Army Annual progress report [Link]
PubChem Substance
347910450
RxNav
227410

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
OintmentTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on November 30, 2015 12:10 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates